US Patent

US7560076 — Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)

Formulation · Assigned to Geno LLC · Expires 2027-04-21 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a nitric oxide delivery system that converts nitrogen dioxide to nitric oxide using a surface-active material coated with an antioxidant.

USPTO Abstract

Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. A nitric oxide delivery system that converts nitrogen dioxide to nitric oxide employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid.

Drugs covered by this patent

Patent Metadata

Patent number
US7560076
Jurisdiction
US
Classification
Formulation
Expires
2027-04-21
Drug substance claim
No
Drug product claim
Yes
Assignee
Geno LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.